In preclinical experiments on breast cancer cell lines, small-molecule PARP1/PD-L1 inhibitor conjugates demonstrated more significant apoptosis and cytotoxic efficacy compared to their separate agents (11). This evidence concerns the gene PARP1 and breast cancer.